NAD(+) in COVID-19 and viral infections

NAD(+), as an emerging regulator of immune responses during viral infections, may be a promising therapeutic target for coronavirus disease 2019 (COVID-19). In this Opinion, we suggest that interventions that boost NAD(+) levels might promote antiviral defense and suppress uncontrolled inflammation....

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Minyan, Schultz, Michael B., Sinclair, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831132/
https://www.ncbi.nlm.nih.gov/pubmed/35221228
http://dx.doi.org/10.1016/j.it.2022.02.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831132/
https://www.ncbi.nlm.nih.gov/pubmed/35221228
http://dx.doi.org/10.1016/j.it.2022.02.001

Ejemplares similares